Pediatrix Medical Group (MD) stock surged 8.43% in pre-market trading on Thursday, following the release of its better-than-expected fourth quarter 2024 results and an upbeat outlook for 2025.
For the fourth quarter, the company reported adjusted earnings per share of $0.51, beating the consensus estimate of $0.37. Revenue of $502.4 million also topped expectations of $486.2 million, driven by an 8.7% increase in same-unit revenue.
Looking ahead, Pediatrix anticipates its 2025 Adjusted EBITDA to range between $215 million and $235 million, reflecting continued growth and operational efficiency efforts. The company expects to benefit from its recent portfolio restructuring and overhead expense reductions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。